Encyclopedia entry
Bariatric surgery vs GLP-1 medications
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Bariatric surgery and GLP-1 medications are complementary NHS weight management pathways, not competing alternatives. GLP-1 prescribing sits at Tier 3 in the NHS framework; bariatric surgery sits at Tier 4. The standard NHS sequence is: Tier 3 trial first, Tier 4 escalation if outcomes are insufficient. Both pathways have distinct strengths.
Typical weight loss
- · Mounjaro at maintenance dose: 20 to 22 percent average weight loss over 72 weeks (SURMOUNT-1).
- · Wegovy at maintenance dose: 14 to 15 percent average over 68 weeks (STEP-1).
- · Gastric sleeve: 25 to 30 percent total body weight loss at 12 to 24 months, typically sustained.
- · Gastric bypass: 30 to 35 percent total body weight loss at 12 to 24 months.
- · Gastric band: 15 to 20 percent, less commonly performed in 2026 due to revision rates.
Strengths and trade-offs
- GLP-1 medications: non-invasive, reversible (stop the medication and regain typically follows within 12 to 18 months), broadly tolerated, ongoing monthly cost or NHS-funded if eligible.
- Bariatric surgery: one-time intervention with one-time cost, sustained outcomes if the patient maintains the dietary changes, but surgical risk, irreversible anatomical change (for sleeve and bypass), and requires lifelong nutritional supplementation.
Can GLP-1 follow bariatric surgery
Yes. Post-bariatric weight regain is common (20 to 30 percent of patients regain meaningful weight by year 5). GLP-1 prescribing for post-bariatric regain is increasingly common in 2026, both privately and through NHS Tier 3 routes. The two are stacked rather than substituted.
GLP-1 medications vs bariatric surgery at a glance
| Feature | GLP-1 medications | Bariatric surgery |
|---|---|---|
| NHS tier | Tier 3 | Tier 4 |
| Typical weight loss | 14 to 22% average in trials (Wegovy 14 to 15%, Mounjaro 20 to 22%) | 25 to 35% total body weight (sleeve 25 to 30%, bypass 30 to 35%) |
| Invasiveness | Non-invasive injection | Surgical, anatomical change (sleeve, bypass) |
| Reversibility | Reversible; regain typically follows within 12 to 18 months of stopping | Largely irreversible for sleeve and bypass |
| Cost pattern | Ongoing monthly, or NHS-funded if eligible | One-time intervention and cost |
| Ongoing requirements | Continued prescribing and clinical review | Lifelong nutritional supplementation |
Editorial comparison of two complementary NHS pathways. Not a recommendation. Whether either pathway is appropriate, and in what sequence, is a decision for your clinical team.
Frequently asked questions
Are GLP-1 medications and bariatric surgery competing options?
No. They are complementary NHS pathways. GLP-1 prescribing sits at Tier 3 and bariatric surgery at Tier 4. The standard NHS sequence is a Tier 3 trial first, with Tier 4 escalation if outcomes are insufficient.
Can I take a GLP-1 medication after bariatric surgery?
It happens in practice. Post-bariatric weight regain is common (20 to 30 percent of patients by year 5), and GLP-1 prescribing for regain is increasingly used in 2026, both privately and through NHS Tier 3 routes. Whether it is appropriate is a decision for your clinical team.
Does surgery lose more weight than medication?
Surgical averages (25 to 35 percent total body weight) are higher than medication trial averages (14 to 22 percent), but the trade-offs differ: surgery is largely irreversible with surgical risk and lifelong supplementation, while medication is non-invasive and reversible. The right pathway for any individual is a clinical decision, not a single number.
Related: Tier 3 / Tier 4 · NICE TA1026.